Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/45870
Full metadata record
DC FieldValueLanguage
dc.contributor.authorONG, Fenny-
dc.contributor.authorMOLENBERGHS, Geert-
dc.contributor.authorCallegaro, Andrea-
dc.contributor.authorVAN DER ELST, Wim-
dc.contributor.authorVERBEKE, Geert-
dc.contributor.authorStijven, Florian-
dc.contributor.authorKeilegom, Ingrid Van-
dc.contributor.authorAbad, Ariel Alonso-
dc.date.accessioned2025-04-17T08:43:18Z-
dc.date.available2025-04-17T08:43:18Z-
dc.date.issued2025-
dc.date.submitted2025-04-11T13:12:23Z-
dc.identifier.citationJournal of Global Infectious Diseases, 17 (1) , p. 17 -23-
dc.identifier.urihttp://hdl.handle.net/1942/45870-
dc.description.abstractIntroduction:Identifying hemagglutination inhibition (HI) antibody titers as a key immune correlate of protection (CoP) is crucial for developing, licensing, and monitoring the ongoing effectiveness of new influenza vaccines. Using a new statistical methodology, we explored the link between an inactivated quadrivalent influenza vaccine's impact on HI antibody titers and its effectiveness against A/H1N1-associated influenza illness.Methods:We utilized data from a phase 3, observer-blind, randomized, controlled trial in children aged 6-35 months to assess HI antibody titers as an immune CoP. The assessment used a statistical method developed within a causal inference framework and a new information-theoretic metric of surrogacy, the so-called individual causal association (ICA).Results:The 75% and 85% uncertainty intervals of the ICA are 0.5511-0.8282 and 0.3632-0.8684, respectively, indicating a substantial reduction in the uncertainty about the vaccine's effect on the absence of infection when its impact on the HI antibody titers is known.Conclusions:The evaluation yielded evidence supporting the validity of HI antibody titers as a CoP for influenza infection.-
dc.description.sponsorshipThis work was supported by the Special Research Fund (BOF) of Hasselt University (BOF‑number: BOF2OCPO3) and GlaxoSmithKline Biologicals to FO, Baekeland Mandaat(HBC.2022.0145) and Janssen Pharmaceuticals to FS.-
dc.language.isoen-
dc.publisherWOLTERS KLUWER MEDKNOW PUBLICATIONS-
dc.rights2025 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution‑NonCommercial‑ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non‑commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.-
dc.subject.otherCausal inference-
dc.subject.othercorrelate of protection-
dc.subject.otherhemagglutination inhibition antibody titer-
dc.subject.otherinformation theory-
dc.subject.otherreverse transcription-polymerase chain reaction-confirmed influenza-
dc.subject.othersurrogate-
dc.titleEvaluating Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Influenza: A Sensitivity Analysis Based on Information Theory and Causal Inference-
dc.typeJournal Contribution-
dc.identifier.epage23-
dc.identifier.issue1-
dc.identifier.spage17-
dc.identifier.volume17-
local.format.pages7-
local.bibliographicCitation.jcatA1-
dc.description.notesOng, F (corresponding author), Univ Hasselt, I BioStat, B-3590 Diepenbeek, Belgium.-
dc.description.notesfenny.ong@uhasselt.be-
local.publisher.placeWOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.4103/jgid.jgid_89_24-
dc.identifier.isi001456291500006-
local.provider.typewosris-
local.description.affiliation[Ong, Fenny; Molenberghs, Geert] Univ Hasselt, I BioStat, B-3590 Diepenbeek, Belgium.-
local.description.affiliation[Molenberghs, Geert; Verbeke, Geert; Stijven, Florian; Abad, Ariel Alonso] Katholieke Univ Leuven, I Biostat, Leuven, Belgium.-
local.description.affiliation[Callegaro, Andrea] GSK Vaccines, Rixensart, Belgium.-
local.description.affiliation[van der Elst, Wim] Janssen Pharmaceut Co Johnson & Johnson, Beerse, Belgium.-
local.description.affiliation[Keilegom, Ingrid Van] Katholieke Univ Leuven, ORSTAT, Leuven, Belgium.-
local.uhasselt.internationalno-
item.fulltextWith Fulltext-
item.contributorONG, Fenny-
item.contributorMOLENBERGHS, Geert-
item.contributorCallegaro, Andrea-
item.contributorVAN DER ELST, Wim-
item.contributorVERBEKE, Geert-
item.contributorStijven, Florian-
item.contributorKeilegom, Ingrid Van-
item.contributorAbad, Ariel Alonso-
item.fullcitationONG, Fenny; MOLENBERGHS, Geert; Callegaro, Andrea; VAN DER ELST, Wim; VERBEKE, Geert; Stijven, Florian; Keilegom, Ingrid Van & Abad, Ariel Alonso (2025) Evaluating Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Influenza: A Sensitivity Analysis Based on Information Theory and Causal Inference. In: Journal of Global Infectious Diseases, 17 (1) , p. 17 -23.-
item.accessRightsOpen Access-
crisitem.journal.issn0974-777X-
crisitem.journal.eissn0974-8245-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
ATAO_TX_1~ABS_ABSH_AT_HTC_OS_ADD_TX_2~ABS_ABSH_AT.pdfPublished version843.65 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.